

Resource Summary Report

Generated by [NIF](#) on Sep 18, 2026

Brilliant Violet 605(TM) anti-human CD5

RRID:AB_2565941

Type: Antibody

Proper Citation

BioLegend Cat# 364020, RRID:AB_2565941

Antibody Information

URL: http://antibodyregistry.org/AB_2565941

Proper Citation: BioLegend Cat# 364020, RRID:AB_2565941

Target Antigen: CD5

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 605(TM) anti-human CD5

Description: This monoclonal targets CD5

Target Organism: human

Clone ID: Clone L17F12

Antibody ID: AB_2565941

Vendor: BioLegend

Catalog Number: 364020

Alternative Catalog Numbers: 364019

Record Creation Time: 20231110T035156+0000

Record Last Update: 20260830T030802+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 605(TM) anti-human CD5.

No alerts have been found for Brilliant Violet 605(TM) anti-human CD5.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Cheng J, et al. (2026) Efficacy and safety of autologous CD5-KO anti-CD5 CAR-T cells in relapsed/refractory CD5+ hematological malignancies. Cell reports. Medicine, 7(2), 102584.

Stankiewicz LN, et al. (2025) Sex-biased human thymic architecture guides T cell development through spatially defined niches. Developmental cell, 60(1), 152.

Zhang Y, et al. (2024) Generation of dual-attribute iTNK cells from hPSCs for cancer immunotherapy. Cell reports methods, 4(9), 100843.

Lameris R, et al. (2023) A bispecific T cell engager recruits both type 1 NKT and V α 9V β 2-T cells for the treatment of CD1d-expressing hematological malignancies. Cell reports. Medicine, 4(3), 100961.